| 2.5948 -0.125 (-4.6%) | 11-07 10:04 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.23  |
1-year : | 16.27 |
| Resists | First : | 9.62 |
Second : | 13.93 |
| Pivot price | 3.4 |
|||
| Supports | First : | 2.65 |
Second : | 2.2 |
| MAs | MA(5) : | 2.82 |
MA(20) : | 3.74 |
| MA(100) : | 3.53 |
MA(250) : | 3.55 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 1.6  |
D(3) : | 1.1 |
| RSI | RSI(14): 37.9 |
|||
| 52-week | High : | 13.93 | Low : | 2.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ XBIO ] has closed above bottom band by 11.0%. Bollinger Bands are 11.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.78 - 2.8 | 2.8 - 2.82 |
| Low: | 2.61 - 2.64 | 2.64 - 2.66 |
| Close: | 2.68 - 2.72 | 2.72 - 2.75 |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Fri, 31 Oct 2025
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - York Dispatch
Thu, 30 Oct 2025
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - Rockford Register Star
Tue, 14 Oct 2025
Xenetic Biosciences Announces Public Offering Pricing - TipRanks
Fri, 10 Oct 2025
Xenetic (XBIO) Sets Pricing for New Stock Offering - GuruFocus
Fri, 10 Oct 2025
Xenetic Biosciences prices $4.5 million common stock offering - Investing.com
Fri, 10 Oct 2025
$4.5M offering: Xenetic Biosciences prices 735,000 shares to fund working capital - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 12.9 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 62 (K) |
| Shares Short P.Month | 23 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.88 |
| Profit Margin | -126.1 % |
| Operating Margin | -122.9 % |
| Return on Assets (ttm) | -28.4 % |
| Return on Equity (ttm) | -51.9 % |
| Qtrly Rev. Growth | -18.8 % |
| Gross Profit (p.s.) | 1.07 |
| Sales Per Share | 1.07 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.34 |
| PEG Ratio | 0 |
| Price to Book value | 0.92 |
| Price to Sales | 2.48 |
| Price to Cash Flow | -2.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|